CD163、PD-L1和FoxP3阳性细胞浸润独立于既定风险因素对套细胞淋巴瘤患者结局产生不良影响
该研究在282例套细胞淋巴瘤(MCL)患者中分析肿瘤细胞标志物Cyclin D1、SOX11及免疫标志物CD3、CD4、CD8、CD25、FoxP3、T-bet、PD-1、PD-L1和CD163的表达与全因死亡率的关系,并在106例临床试验患者中分析至进展时间(TTP)。结果显示PD-L1表达高于界值及CD163阳性细胞频率较高与全因死亡率升高相关;在北欧淋巴瘤组MCL2/3试验患者中,FoxP3阳性细胞和CD163阳性细胞频率较高与TTP缩短相关,且这些关联独立于性别和MIPI。CD163阳性巨噬细胞与PD-L1阳性细胞或FoxP3阳性调节性T细胞同时高频率提示更差结局,独立于既定风险因素。
要点
- CD163阳性细胞频率较高与全因死亡率升高及TTP缩短独立相关。
核心结论
- PD-L1高表达和CD163阳性细胞高频率与MCL患者全因死亡率升高独立相关。
- FoxP3阳性细胞和CD163阳性细胞高频率与临床试验患者TTP缩短独立相关。
- CD163阳性巨噬细胞与PD-L1阳性细胞或FoxP3阳性调节性T细胞同时高频率提示更差结局,独立于既定风险因素。
- T细胞浸润独立于肿瘤细胞分子特征,且随年龄增长而降低。
研究设计与样本
- 研究纳入282例MCL患者分析全因死亡率,另在106例临床试验患者中分析TTP。
- 检测肿瘤细胞标志物Cyclin D1、SOX11及免疫标志物CD3、CD4、CD8、CD25、FoxP3、T-bet、PD-1、PD-L1和CD163。
主要发现
- CD163阳性巨噬细胞与PD-L1阳性细胞或FoxP3阳性调节性T细胞同时高频率提示更差结局,独立于既定风险因素。
临床怎么用
- 可考虑检测MCL肿瘤微环境中PD-L1、CD163和FoxP3阳性细胞浸润以辅助风险分层。
- CD163阳性巨噬细胞与PD-L1阳性细胞或FoxP3阳性调节性T细胞联合高频率可能识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We characterised patients with mantle cell lymphoma (MCL) with poor prognosis based on differences in immune infiltration. Different expressions of the tumour cell markers Cyclin D1 and sex-determining region Y-box transcription factor 11 (SOX11), and the immune markers cluster of differentiation 3 (CD3), CD4, CD8, CD25, forkhead box protein P3 (FoxP3), T-box transcription factor TBX21 (T-bet), programmed cell death protein 1 (PD-1), programmed-death ligand 1 (PD-L1) and CD163 were investigated for all-cause mortality in 282 patients with MCL and time-to-progression (TTP) in 106 clinical trial patients. With increasing age, a significantly lower infiltration of CD3+ T lymphocytes was seen. T-cell infiltration was independent of cellular tumour antigen p53 (p53) expression, Ki-67, morphology and frequency of tumour cells. The all-cause mortality was higher in patients with PD-L1-expression above cut-off [hazard ratio (HR) 1·97, 95% confidence interval (CI) 1·18-3·25, adjusted for sex and MCL International Prognostic Index (MIPI)] and a higher frequency of CD163+ cells (continuously, HR 1·51, 95% CI 1·03-2·23, adjusting for age, sex, morphology, Ki-67 and p53). In patients treated within the Nordic Lymphoma Group MCL2/3 trials, TTP was shorter in patients with a higher frequency of FoxP3+ cells (HR 3·22, 95% CI 1·40-7·43) and CD163+ cells (HR 6·09, 95% CI 1·84-20·21), independent of sex and MIPI. When combined a higher frequency of CD163+ macrophages and PD-L1+ cells or high CD163+ macrophages and FoxP3+ regulatory T cells indicated worse outcome independent of established risk factors. The T-cell infiltrate was in turn independent of molecular characteristics of the malignant cells and decreased with age.
引用
- Rodrigues JM, Nikkarinen A, Hollander P, et al. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. Br J Haematol. 2021. PMID: 33686666. doi:10.1111/bjh.17366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。